HRAS and cancer: While activating mutations in KRas, NRas and HRas genes have long been recognized and occur in many types of cancer, genetic dysregulation of Rho family GTPases, such as Rac1 and RhoA, have only recently been characterized as the result of extensive cancer genome-sequencing efforts and are associated with rather specific types of cancer.